News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Regado Biosciences, Inc. (RGDO) To Present At The 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference


2/4/2014 7:11:49 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

BASKING RIDGE, N.J., Feb. 4, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will present at the 16th Annual BIO CEO & Investor Conference taking place Feb. 10-11, 2014, at the Waldorf Astoria in New York City.

David J. Mazzo, Ph.D., chief executive officer of Regado Biosciences, will provide a corporate update during his presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

A live audio webcast of the presentation will be available under the investor relations section of Regado's website at www.regadobio.com. A replay of the presentation will be available for 90 days following the event.

Date:

Monday, Feb. 10, 2014

Time:

10 a.m. EST

Location:

Waldorf Astoria, New York City

ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc., is a biopharmaceutical company focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. Regado is pioneering the development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a world-wide Phase 3 study enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes, enhance the patient experience and reduce overall treatment costs. More information can be found at www.regadobio.com.

For more information on REGULATE-PCI, please visit:
http://www.clinicaltrials.gov/ct2/show/NCT01848106

Media Contacts:

David Schull or Lena Evans
Russo Partners
212-845-4271
212-845-4262
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com

Investor Relations Contacts:

Tricia Truehart or Chelsea Wheeler
Trout Group
646-378-2953
646-378-2941
regadobio@troutgroup.com

SOURCE Regado Biosciences, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES